Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models

Tumor heterogeneity and drug resistance pose severe limitations to chemotherapy of colorectal cancers (CRCs) necessitating innovative approaches to trigger multiple cytocidal events for increased efficacy. Here, we developed a hybrid drug called KSS19 by combining the COX-2 selective NSAID rofecoxib...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Punganuru, Surendra R., Madala, Hanumantha Rao, Mikelis, Constantinos M., Dixit, Anshuman, Arutla, Viswanath, Srivenugopal, Kalkunte S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995258/
https://ncbi.nlm.nih.gov/pubmed/29899846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25450
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi